36 related articles for article (PubMed ID: 30918068)
1. The expression of proenkephalin and prodynorphin genes and the induction of c-fos gene by dopaminergic drugs are not altered in the straitum of MPTP-treated mice.
Ziolkowska B; Horn G; Kupsch A; Höllt V
J Neural Transm Park Dis Dement Sect; 1995; 9(2-3):151-64. PubMed ID: 8527000
[TBL] [Abstract][Full Text] [Related]
2. Metformin and Trehalose-Modulated Autophagy Exerts a Neurotherapeutic Effect on Parkinson's Disease.
Gopar-Cuevas Y; Saucedo-Cardenas O; Loera-Arias MJ; Montes-de-Oca-Luna R; Rodriguez-Rocha H; Garcia-Garcia A
Mol Neurobiol; 2023 Dec; 60(12):7253-7273. PubMed ID: 37542649
[TBL] [Abstract][Full Text] [Related]
3. Development of Alpha-Synuclein protein model against therapeutic aspects of Parkinson's disease.
Bhardwaj K; Rajawat NK; Mathur N
Indian J Pharmacol; 2024 Jan; 56(1):37-41. PubMed ID: 38454587
[TBL] [Abstract][Full Text] [Related]
4. Trehalose against Alzheimer's Disease: Insights into a Potential Therapy.
Khalifeh M; Read MI; Barreto GE; Sahebkar A
Bioessays; 2020 Aug; 42(8):e1900195. PubMed ID: 32519387
[TBL] [Abstract][Full Text] [Related]
5. Trehalose Inhibits Aβ Generation and Plaque Formation in Alzheimer's Disease.
Liu Y; Wang J; Hsiung GR; Song W
Mol Neurobiol; 2020 Jul; 57(7):3150-3157. PubMed ID: 32488697
[TBL] [Abstract][Full Text] [Related]
6. Cell reprogramming therapy for Parkinson's disease.
Dong W; Liu S; Li S; Wang Z
Neural Regen Res; 2024 Nov; 19(11):2444-2455. PubMed ID: 38526281
[TBL] [Abstract][Full Text] [Related]
7. Pathogenic Aspects and Therapeutic Avenues of Autophagy in Parkinson's Disease.
Kinet R; Dehay B
Cells; 2023 Feb; 12(4):. PubMed ID: 36831288
[TBL] [Abstract][Full Text] [Related]
8. Profiling neuroprotective potential of trehalose in animal models of neurodegenerative diseases: a systematic review.
Yap KH; Azmin S; Makpol S; Damanhuri HA; Mustapha M; Hamzah JC; Ibrahim NM
Neural Regen Res; 2023 Jun; 18(6):1179-1185. PubMed ID: 36453391
[TBL] [Abstract][Full Text] [Related]
9. Therapeutics in the Pipeline Targeting
Grosso Jasutkar H; Oh SE; Mouradian MM
Pharmacol Rev; 2022 Jan; 74(1):207-237. PubMed ID: 35017177
[TBL] [Abstract][Full Text] [Related]
10. Autophagy-targeted therapy to modulate age-related diseases: Success, pitfalls, and new directions.
Martins WK; Silva MDND; Pandey K; Maejima I; Ramalho E; Olivon VC; Diniz SN; Grasso D
Curr Res Pharmacol Drug Discov; 2021; 2():100033. PubMed ID: 34909664
[TBL] [Abstract][Full Text] [Related]
11. Potential Fast COVID-19 Containment With Trehalose.
Martinon D; Borges VF; Gomez AC; Shimada K
Front Immunol; 2020; 11():1623. PubMed ID: 32733488
[TBL] [Abstract][Full Text] [Related]
12. Alpha-Synuclein and LRRK2 in Synaptic Autophagy: Linking Early Dysfunction to Late-Stage Pathology in Parkinson's Disease.
Lamonaca G; Volta M
Cells; 2020 Apr; 9(5):. PubMed ID: 32365906
[TBL] [Abstract][Full Text] [Related]
13. Targeting α-synuclein for PD Therapeutics: A Pursuit on All Fronts.
Teil M; Arotcarena ML; Faggiani E; Laferriere F; Bezard E; Dehay B
Biomolecules; 2020 Mar; 10(3):. PubMed ID: 32138193
[TBL] [Abstract][Full Text] [Related]
14. Stem cell therapy for Parkinson's disease using non-human primate models.
Chen ZZ; Niu YY
Zool Res; 2019 Sep; 40(5):349-357. PubMed ID: 31343853
[TBL] [Abstract][Full Text] [Related]
15. Beneficial Effects of Trehalose on Striatal Dopaminergic Deficits in Rodent and Primate Models of Synucleinopathy in Parkinson's Disease.
Howson PA; Johnston TH; Ravenscroft P; Hill MP; Su J; Brotchie JM; Koprich JB
J Pharmacol Exp Ther; 2019 Jun; 369(3):364-374. PubMed ID: 30918068
[TBL] [Abstract][Full Text] [Related]
16. Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV α-Synuclein Rat Model of Parkinson's Disease.
He Q; Koprich JB; Wang Y; Yu WB; Xiao BG; Brotchie JM; Wang J
Mol Neurobiol; 2016 May; 53(4):2258-68. PubMed ID: 25972237
[TBL] [Abstract][Full Text] [Related]
17. Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein.
Koprich JB; Johnston TH; Huot P; Reyes MG; Espinosa M; Brotchie JM
PLoS One; 2011 Mar; 6(3):e17698. PubMed ID: 21408191
[TBL] [Abstract][Full Text] [Related]
18. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
[TBL] [Abstract][Full Text] [Related]
19. alpha-Synuclein- and MPTP-generated rodent models of Parkinson's disease and the study of extracellular striatal dopamine dynamics: a microdialysis approach.
Bazzu G; Calia G; Puggioni G; Spissu Y; Rocchitta G; Debetto P; Grigoletto J; Zusso M; Migheli R; Serra PA; Desole MS; Miele E
CNS Neurol Disord Drug Targets; 2010 Aug; 9(4):482-90. PubMed ID: 20522009
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
